Table 1 qHTS assay summary statistics

From: Profiling of the Tox21 10K compound library for agonists and antagonists of the estrogen receptor alpha signaling pathway

Assay S/B* CV (%)* Z' factor Positive Control Positive Control AC50 (M) (±fold)
HEK293 ER-bla agonist 4.6 ± 0.6 4.7 ± 3.7 0.53 ± 0.09 17 β-Estradiol 3.14 × 10−10 (1.4)
HEK293 ER-bla antagonist 3.3 ± 0.8 5.1 ± 2.8 0.41 ± 0.10 Tamoxifen 5.01 × 10−9 (1.4)
HEK293 ER-bla viability 132.6 ± 8.2 9.4 ± 2.5 0.76 ± 0.06 Tetra n-octyl ammonium bromide N/A
BG1 ER-luc agonist 2.5 ± 0.3 10.3 ± 4.6 0.50 ± 0.25 17 β-Estradiol 2.74 × 10−11 (2.8)
BG1 ER-luc antagonist 8.0 ± 0.9 6.5 ± 2.8 0.77 ± 0.07 Tamoxifen 7.30 × 10−8 (1.1)
BG1 ER-luc viability 6.1 ± 0.9 7.2 ± 2.1 0.81 ± 0.06 Tetra n-octyl ammonium bromide N/A
  1. Data presented as mean ± standard deviation.
  2. *S/B = Signal to Background, CV = Coefficient of Variance, AC50 = Concentration at 50% activity.